Is lacosamide (Vimpat) as effective as levetiracetam (Keppra) for focal onset seizures?

Lacosamide (Vimpat) and Levetiracetam (Keppra) Show Equivalent Efficacy for Focal Onset Seizures

Both lacosamide and levetiracetam demonstrate comparable effectiveness for focal onset seizures, with levetiracetam maintaining a slight edge as the preferred first-line option due to more extensive clinical experience and guideline support, though lacosamide represents an excellent alternative particularly when levetiracetam is not tolerated.

Guideline-Based Recommendations

The most recent neuro-oncology guidelines (2021) establish levetiracetam as the preferred first-choice antiseizure medication for brain tumor-related seizures, with lacosamide specifically mentioned as an add-on treatment for patients whose seizures are not controlled by monotherapy 1. This reflects the broader clinical consensus that levetiracetam has become "the drug of first choice at most neuro-oncology centres in recent years" 1.

Emergency medicine guidelines (2014) provide Level C recommendations for both agents in status epilepticus, indicating they may be administered after benzodiazepine failure 2. The evidence quality for both drugs in acute seizure management is similar, with multiple Class III studies showing efficacy rates of 67-73% for levetiracetam 2 and comparable performance for lacosamide when used as add-on therapy 1.

Direct Comparative Evidence

Monotherapy Studies

The highest quality direct comparison comes from a 2023 randomized controlled trial specifically designed as a non-inferiority study 3. This study enrolled 70 patients with new-onset focal epilepsy (35 per arm) and demonstrated:

• Seizure frequency reduction: Both groups showed significant improvement (lacosamide: 3.33±1.88 to 0.85±1.09; levetiracetam: 3.61±3.12 to 0.94±1.24, p=0.74 between groups)
• 50% responder rates: 78.9% for lacosamide vs 87.9% for levetiracetam
• Seizure freedom at 6 months: Identical at 43.3% in both arms (p=1.0)
• Conclusion: Lacosamide met non-inferiority criteria 3

A 2019 retrospective study in elderly patients (≥65 years) showed similar long-term outcomes 4:

• Seizure freedom at 12 months: 72.7% with lacosamide vs 70.8% with levetiracetam
• Mean seizure reduction: Both groups showed significant improvement (p<0.001)
• Notable: Lacosamide achieved these results at lower doses (mean 204.5 mg/day) 4

Add-On Therapy Studies

A 2018 retrospective comparison of add-on therapy found no significant differences in efficacy 5:

• Both groups showed significant seizure reduction at 3 and 6 months (p<0.005)
• No statistical difference in seizure control rates between groups (p=0.238)

The 2022 Cochrane network meta-analysis of 14,789 participants provides the most comprehensive indirect comparison 6. For focal seizures, the analysis showed:

• Lamotrigine and levetiracetam performed best overall for treatment failure outcomes
• Lacosamide showed no significant differences compared to levetiracetam in head-to-head network comparisons
• High-certainty evidence supports levetiracetam as first-line, but lacosamide performs comparably

Status Epilepticus

A 2025 large cohort analysis of 961 adult status epilepticus episodes found statistically equivalent outcomes when comparing lacosamide, levetiracetam, and valproate as second-line therapy 7:

• Equivalent seizure cessation rates
• Similar need for mechanical ventilation
• Comparable clinical outcomes at discharge
• Conclusion: "Lacosamide appears to represent a reasonable alternative to levetiracetam" 7

Tolerability Profile

Levetiracetam

• Common adverse effects: Somnolence, behavioral abnormalities (irritability, aggression, mood changes) 3
• Psychiatric concerns: Guidelines specifically note "psychiatric side-effects in some patients remain a concern" 1
• Advantage: No significant drug interactions, no enzyme induction 1

Lacosamide

• Common adverse effects: Fatiguability, dyspepsia, headache, dizziness 3
• Cardiac considerations: Can cause PR interval prolongation and bradycardia (16.6% in one safety study) 8, though generally well-tolerated
• Advantage: Lower incidence of behavioral/psychiatric effects compared to levetiracetam 4
• Drug interactions: Minimal; does not affect other antiseizure medication levels 9

A 2024 driving performance review found both drugs had equivalent safety profiles with no clinically meaningful driving impairment during continued administration 10.

Clinical Decision Algorithm

Choose Levetiracetam when:

• First-line monotherapy for newly diagnosed focal epilepsy (guideline-supported) 1, 6
• Patient has cardiac conduction abnormalities or bradycardia
• Broader evidence base desired
• Cost is a primary consideration (typically less expensive)

Choose Lacosamide when:

• Patient has psychiatric history or behavioral concerns with levetiracetam 1, 3
• Elderly patients with multiple comorbidities (favorable pharmacokinetic profile) 4
• Levetiracetam has failed or caused intolerable side effects
• Add-on therapy needed for refractory seizures 1
• Patient requires cardiac monitoring capability (for PR interval assessment)

Either agent is appropriate for:

• Status epilepticus as second-line therapy (after benzodiazepines) 7
• Add-on therapy in refractory focal epilepsy 5, 11
• Patients without specific contraindications to either drug

Key Caveats

1. FDA approval status: Lacosamide is FDA-approved only as adjunctive therapy for focal seizures in patients ≥17 years 9, though real-world evidence supports monotherapy use 3, 4

2. Pediatric use: Levetiracetam has more extensive pediatric data. Lacosamide shows promise in children but with less robust evidence 12

3. Cardiac monitoring: Lacosamide requires baseline ECG in patients with cardiac disease or taking other PR-prolonging medications 9

4. Dose considerations: Lacosamide often achieves efficacy at lower doses in elderly patients (mean 204.5 mg/day vs typical 200-400 mg/day) 4

5. Administration: Both can be safely administered as rapid IV push over 5 minutes when needed 8, though traditional infusion remains standard

The evidence demonstrates that while levetiracetam maintains guideline preference based on extensive clinical experience, lacosamide performs equivalently in direct comparisons and offers distinct advantages in specific patient populations, particularly those with psychiatric comorbidities or elderly patients requiring favorable drug interaction profiles.